fatty-liver

Documents about fatty-liver

• Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease#376075PubMed Central
• MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism#872739ClinicalTrials.gov
• LEPTIN LEVEL IN NON DIABETIC POPULATION WITH AND WITHOUT NON ALCOHOLIC FATTY LIVER (NAFL)#930347Acta Interna: The Journal of Internal Medicine
• LEPTIN LEVEL IN NON DIABETIC POPULATION WITH AND WITHOUT NON ALCOHOLIC FATTY LIVER (NAFL)#930350Acta Interna: The Journal of Internal Medicine
• Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease#266498Europe PMC
• Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease#858340ClinicalTrials.gov
• Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease.#954803Koc University Digital Collections
• Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer#993261ClinicalTrials.gov
• CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome#908699ClinicalTrials.gov
• Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease#136266ClinicalTrials.gov
• Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver#148676ClinicalTrials.gov
• Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)#870936ClinicalTrials.gov
• Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease#879984ClinicalTrials.gov
• 12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat#873287ClinicalTrials.gov
• Amlexanox for Type 2 Diabetes and Obesity#143764ClinicalTrials.gov
• Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome#152616ClinicalTrials.gov
• Epigenetic Mechanisms and Severe Obesity (Biological Tissue Collection)#230318ClinicalTrials.gov
• Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease#284242HAL (France)
• Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD#432857ClinicalTrials.gov
• Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study#628633ClinicalTrials.gov
• Dietary Protein and Hepatic Fat Accumulation#860720ClinicalTrials.gov
• Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis#864904ClinicalTrials.gov
• The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease#879675ClinicalTrials.gov
• A Phase 2b Study of Icosabutate in Fatty Liver Disease#880808ClinicalTrials.gov
• Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients#967675ClinicalTrials.gov
• Peripheral and central mechanisms through which high energy diets impair hippocampal-dependent memory in male rats#492347ScholarWorks@GSU
• Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!#811490ClinicalTrials.gov
• Clinical Study of Serum Fetuin A Level, Insulin Resistance and Hepatic Fat Content in Dialysis Patients#899536ClinicalTrials.gov
• A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor#829266ClinicalTrials.gov
• Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)#883412ClinicalTrials.gov
• The regulation of intrahepatic fatty acid partitioning within the human liver: the effect of sex#215668Ora Oxford University Research
• Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD#261460ClinicalTrials.gov
• The purinergic receptor P2X4R stimulates macro-autophagy with impact on lipid droplet size in fatty liver#284372HAL (France)
• Hepatic Metabolic Changes in Response to Glucagon Infusion#329479ClinicalTrials.gov
• Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans#414375ClinicalTrials.gov
• Identification of circadian rhythm-associated key genes in metabolic dysfunction-associated fatty liver disease.#422958NCBI PubMed Central
• NAFLD Among Patients With Type 2 Diabetes and CKD#481726ClinicalTrials.gov
• Evaluate Patients With Chronic Hepatitis by Three-dimensional Force-controlled Ultrasound Measurement#910938ClinicalTrials.gov
• NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life#913220ClinicalTrials.gov
• Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes#123634ClinicalTrials.gov
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes#175082ClinicalTrials.gov
• Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements#841428ClinicalTrials.gov
• Gut Microbiota and Modulation of Liver Damage in NAFLD#966900ClinicalTrials.gov
• Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)#812991ClinicalTrials.gov
• Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons#311014ClinicalTrials.gov
• Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.#864362ClinicalTrials.gov
• Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD#267991ClinicalTrials.gov
• The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease#287515ClinicalTrials.gov
• Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD#303600ClinicalTrials.gov
• Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome#314297ClinicalTrials.gov